Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy.
Damian JaggiThanoosha NagamanyAndreas EbneterMarion MunkSebastian WolfMartin Sebastian ZinkernagelPublished in: The British journal of ophthalmology (2020)
After 4 years of treatment, initial vision gains were maintained with a reasonable treatment burden, even without an initial loading phase. Our results on functional outcomes are comparable with large controlled studies.